Patients with severe but stable low ejection fraction heart failure (see inclusion criteria below) are candidates for enrollment in the proposed trial. LV ejection fraction can be determined by echocardiography, radionuclide or LV angiography within 12-months of enrollment, and should be assessed when the patient is on optimal therapy (referring cardiologist opinion) for at least 14 days. Patients will be candidates for diagnostic cardiac catheterization to rule out treatable causes of heart failure or will be willing to undergo elective catheterization for this study. All patients disease will undergo dobutamine echocardiography prior to enrollment to assess the extent of jeopardized viable myocardium.

Inclusion Criteria

• Male or non-pregnant female patients aged 18 to 80 years of age ≥3-month history of heart failure
• Compensated (stable) CHF not on intravenous inotropes, vasodilators or diuretics, on optimal medical therapy as defined by AHA/ACC Guidelines
• LV ejection fraction (on optimal therapy) of ≤35%
• Implantable cardiac defibrillator (ICD)
• At least one major coronary artery (or graft) with <50% proximal obstruction
• Women of child-bearing capacity must have a negative pregnancy test within 2 days of test substance administration, and female and male patients must be willing to use birth control during sex for 6w after test substance administration if the female partner is of child-bearing capacity.

Exclusion Criteria

• Unstable or Class IV angina
• Coronary revascularization planned or predicted in next 6 months
• Ischemic muyocardium in 3 or more regions of a single perfusion bed, as assessed by dobutamine echocardiography
• ≥50% occlusion of an "unprotected" left main coronary artery. If arterial or venous conduits provide blood flow to the distal left coronary dirculation (ie, patent bypass grafts) then left main disease is "protected" and such patients are not excluded. The cardiologist performing the cardiac catheterization will make these decisions.
• 2° AV block (Mobitz 2) or 3° AV block unless pacemaker is present
• Hospitalization for CHF requiring intravenous inotropes or vasodilators in the past 4 weeks
• History of biopsy proven myocarditis
• Myocardial infarction in previous 6 months
• Restrictive, hypertrophic or infiltrative cardiomyopathy or chronic pericarditis angiographic contrast requiring high doses of steroid pre-treatment
• Previous or planned organ transplant recipient or donor
• Thrombocytopenia (<100,000 platelets/μl) or bleeding diathesis
• COPD requiring supplemental oxygen at home
• AST <2 times upper limit of normal or chronic liver disease such as cirrhosis or Hepatitis C Virus (HCV). Patients with HCV are eligible only if both of two conditions are met: a) liver function tests are normal; AND b) liver biopsy is normal or shows only mild fibrosis.
• Current or predicted need for hemodialysis within 12 months or creatinine clearance <30 ml/min, either estimated (MDRD equation) or measured
• CVA, TIA or TIND <6 months prior to enrollment
• Patients who are immunosuppressed by medicines (corticosteroids, methotrexate, cyclophosphamide, cyclosporine), illnesses (AIDS, HIV), or netrophil count <1000/mm^3
• Patients receiving other investigational drug therapy within 30 days of enrollment including gene transfer